(R)-N2-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(4-methoxy-3-(methylsulfonyl)phenyl)-N4-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine | 1203653-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (R)-N2-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(4-methoxy-3-(methylsulfonyl)phenyl)-N4-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine
• 英文别名: N2-((R)-1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(4-methoxy-3-(methylsulfonyl)phenyl)-N4-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine；6-(4-methoxy-3-methylsulfonyl-phenyl)-N2-[(1R)-1-[4-(1,2,4-triazol-1-yl)phenyl]ethyl]-N4-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine；6-(4-methoxy-3-methylsulfonylphenyl)-2-N-[(1R)-1-[4-(1,2,4-triazol-1-yl)phenyl]ethyl]-4-N-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine
• CAS: 1203653-35-3
• 化学式: C₂₇H₂₅F₃N₈O₃S
• 分子量: 598.609
• InChiKey: YCAOUEWMROIKEB-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  145
• 氢给体数：
  2
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  (R)-(+)-1-(4-溴苯基)乙胺 在 potassium phosphate 、 copper(l) iodide 、 四(三苯基膦)钯 、 potassium carbonate 、 N,N-二异丙基乙胺 、 sodium iodide 、 N,N'-二甲基乙二胺 作用下， 以 N-甲基吡咯烷酮 、 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.33h， 生成 (R)-N2-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(4-methoxy-3-(methylsulfonyl)phenyl)-N4-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine
  参考文献：
  名称：

  Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors

  摘要：

  A novel series of HCV replication inhibitors based on a pyrido[3,2-d]primidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).

  DOI：

  10.1021/ml200163b

文献信息

• 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
  申请人：Canales Eda

  公开号：US20110123493A1

  公开（公告）日：2011-05-26

  Pyrido(3,2-d)pyrimidine derivatives represented by the structural formula (Ia): wherein, R 1 , R 2 and R 3 are defined herein, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro-drugs thereof, for use in the treatment of hepatitis C.

  该文描述了结构式(Ia)所代表的吡啶并[3,2-d]嘧啶衍生物：其中，R1、R2和R3在此定义，以及其药物可接受的加合盐、立体化学异构体形式、N-氧化物、溶剂化合物和前药，用于治疗丙型肝炎。
• US8536187B2
  申请人：——

  公开号：US8536187B2

  公开（公告）日：2013-09-17
• Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors
  作者：Scott E. Lazerwith、Gina Bahador、Eda Canales、Guofeng Cheng、Lee Chong、Michael O. Clarke、Edward Doerffler、Eugene J. Eisenberg、Jaclyn Hayes、Bing Lu、Qi Liu、Mike Matles、Michael Mertzman、Michael L. Mitchell、Philip Morganelli、Bernard P. Murray、Margaret Robinson、Robert G. Strickley、Megan Tessler、Neeraj Tirunagari、Jianhong Wang、Yujin Wang、Jennifer R. Zhang、Xubin Zheng、Weidong Zhong、William J. Watkins

  DOI：10.1021/ml200163b

  日期：2011.10.13

  A novel series of HCV replication inhibitors based on a pyrido[3,2-d]primidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).